1. GLP-1 receptor agonists include semaglutide and tirzepatide.
2. Study analyzed 60,860 adults with type 2 diabetes and obesity.
3. GLP-1RA users had lower risks of dementia (HR 0.63) and stroke (HR 0.81).
4. Significant subgroup benefits observed in those aged 60 and older.
5. Semaglutide and tirzepatide promote neuroprotective advantages beyond glycemic control.

Source: JAMA Network